Tech Company Financing Transactions
NanoSyrinx Funding Round
NanoSyrinx closed a $13 million funding round on 9/10/2024. Investors included BGF Ventures, M Ventures and Octopus Ventures.
Transaction Overview
Company Name
Announced On
9/10/2024
Transaction Type
Venture Equity
Amount
$13,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the growth of its platform and the development of biologic therapeutics against a pipeline of previously 'undruggable' intracellular targets.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
The Venture Centre, University of Warwick Science Park
Coventry, CV47EZ
UK
Coventry, CV47EZ
UK
Phone
Undisclosed
Website
Email Address
Overview
Many therapeutics need access to the interiors of cells, where the machinery of life is busy going about its tasks. Historically, reaching the interior of cells with therapeutic molecules has been a recalcitrant problem. NanoSyrinx is a discovery stage synthetic biology company developing a novel system based around naturally occurring 'nanosyringes', to overcome this challenge by delivering therapeutic proteins and peptides direct to the cytosol in a targeted manner.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Edwin Moses
Chief Executive Officer
Joseph Healey
Chief Scientific Officer
Marie McAvoy
VP - Bus. Development
James Lapworth
Browse more venture capital transactions:
Prev: 9/10/2024: CorFlow Therapeutics venture capital transaction
Next: 9/10/2024: Illuma Labs venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs